Trials / Completed
CompletedNCT00228397
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 221 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CCI-779 |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2005-09-28
- Last updated
- 2013-02-13
Source: ClinicalTrials.gov record NCT00228397. Inclusion in this directory is not an endorsement.